B
Barry R. Davis
Researcher at University of Texas at Austin
Publications - 351
Citations - 50989
Barry R. Davis is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Chlorthalidone & Amlodipine. The author has an hindex of 78, co-authored 342 publications receiving 47899 citations. Previous affiliations of Barry R. Davis include Tulane University & Cardiovascular Institute of the South.
Papers
More filters
Research Output of the Canadian Pharmaceutical Industry: Where Has All the R&D Gone? Résultats de recherche dans l'industrie pharmaceutique canadienne : que sont devenus la recherche et le développement?
Sir Mortimer,Barry R. Davis +1 more
Journal ArticleDOI
OR 70: Blood pressure control by randomized drug group in allhat
William C. Cushman,Charles E. Ford,Paula T. Einhorn,Jackson T. Wright,Richard A. Preston,Barry R. Davis,Jan Basile +6 more
TL;DR: The primary aim of the trial was to establish a positive association between blood pressure and antihypertensive agents and the use of these agents in patients with high blood pressure.
Posted ContentDOI
Worsening of kidney function is the major mechanism of heart failure in hypertension: the ALLHAT study
TL;DR: On the risk difference scale, change in eGFR accounts for more than 50% of the mechanism by which antihypertensive medications affect HF.
Journal ArticleDOI
Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials.
Lisa J Woodhouse,Alan A Montgomery,Jonathan Mant,Barry R. Davis,Ale Algra,Jean-Louis Mas,Jan A. Staessen,Lutgarde Thijs,Andrew Tonkin,Adrienne Kirby,Stuart J. Pocock,John Chalmers,Graeme J. Hankey,J. David Spence,Peter Sandercock,Hans-Christoph Diener,Shinichiro Uchiyama,Nikola Sprigg,Philip M.W. Bath +18 more
TL;DR: In this paper, ordinal vascular outcome measures appear to be more efficient statistically than binary outcomes and provide information on the severity of event and suggest a potential role for using ordinal outcomes in vascular prevention trials.
Journal ArticleDOI
Prevention of Stroke in Older Persons With Isolated Systolic Hypertension-Reply
Jeremiah Stamler,Kenneth G. Berge,Barry R. Davis,Evan C. Hadley,Sara L. Pressel,Jeffrey L. Probstfield +5 more
TL;DR: The public health implications of SHEP go well beyond reduction in the incidence of stroke; the treatment used in SHEP could prevent about 4 million people in the United States currently have isolated systolic hypertension, which means the prevention of 55 events per 1000 patients in the first 5 years of treatment.